X4 Pharmaceuticals (XFOR)

• Market cap: $104M
• 1 day: 0.66%
• 5 days: -11.41%
• 1 month: 79.58%
• 3 months: -13.54%
• 6 months: -36.32%
• Year to date: -30.71%
• 1 year: -16.27%
• 5 years: -94.12%
• 10 years: -99.27%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

163% more call options, than puts

Call options by funds: $279K | Put options by funds: $106K

94% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 18

14% more capital invested

Capital invested by funds: $59M [Q2] → $67.3M (+$8.28M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.9% less ownership

Funds ownership: 60.6% [Q2] → 59.7% (-0.9%) [Q3]

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

1% less funds holding

Funds holding: 99 [Q2] → 98 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 145% upside
• Avg. target: $2.75 350% upside
• High target: $4 554% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	145% upside $1.50	Buy Maintained	14 Nov 2024
Stifel Stephen Willey 44% 1-year accuracy 7 / 16 met price target	554% upside $4	Buy Maintained	14 Nov 2024